Education
About Us
Working with TipRanks
Follow Us
CANbridge Pharmaceuticals Inc. (HK:1228)
:1228
RESEARCH TOOLSreports
Total Valuation
CANbridge Pharmaceuticals Inc. has a market cap or net worth of HK$1.27B. The enterprise value is HK$159.36M.
Market CapHK$1.27B
Enterprise ValueHK$159.36M
Share Statistics
CANbridge Pharmaceuticals Inc. has 499,809,780 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding499,809,780
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CANbridge Pharmaceuticals Inc.’s return on equity (ROE) is 0.93 and return on invested capital (ROIC) is 100.53%.
Return on Equity (ROE)0.93
Return on Assets (ROA)-3.79
Return on Invested Capital (ROIC)100.53%
Return on Capital Employed (ROCE)0.93
Revenue Per Employee1.27M
Profits Per Employee-6.61M
Employee Count67
Asset Turnover0.73
Inventory Turnover3.90
Valuation Ratios
The current PE Ratio of CANbridge Pharmaceuticals Inc. is ―. CANbridge Pharmaceuticals Inc.’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value-0.11
Price to FCF0.00
Price to Operating Cash Flow-3.08
PEG Ratio―
Income Statement
In the last 12 months, CANbridge Pharmaceuticals Inc. had revenue of 85.10M and earned -442.62M in profits. Earnings per share was -1.04.
Revenue85.10M
Gross Profit54.30M
Operating Income-340.51M
Pretax Income-442.62M
Net Income-442.62M
EBITDA-328.69M
Earnings Per Share (EPS)-1.04
Cash Flow
In the last 12 months, operating cash flow was -108.30M and capital expenditures -14.00K, giving a free cash flow of -108.31M billion.
Operating Cash Flow-108.30M
Free Cash Flow-108.31M
Free Cash Flow per Share-0.22
Dividends & Yields
CANbridge Pharmaceuticals Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.22
52-Week Price Change775.86%
50-Day Moving Average1.77
200-Day Moving Average0.58
Relative Strength Index (RSI)56.07
Average Volume (3m)14.49M
Important Dates
CANbridge Pharmaceuticals Inc. upcoming earnings date is Mar 26, 2026, Before Open (Not Confirmed).
Last Earnings DateAug 29, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
CANbridge Pharmaceuticals Inc. as a current ratio of 0.09, with Debt / Equity ratio of -28.62%
Current Ratio0.09
Quick Ratio0.08
Debt to Market Cap0.57
Net Debt to EBITDA-0.38
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CANbridge Pharmaceuticals Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CANbridge Pharmaceuticals Inc. EV to EBITDA ratio is -0.54, with an EV/FCF ratio of 0.00.
EV to Sales2.10
EV to EBITDA-0.54
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
CANbridge Pharmaceuticals Inc. has HK$10.50M in cash and marketable securities with HK$135.78M in debt, giving a net cash position of -HK$125.28M billion.
Cash & Marketable SecuritiesHK$10.50M
Total DebtHK$135.78M
Net Cash-HK$125.28M
Net Cash Per Share-HK$0.25
Tangible Book Value Per Share-HK$1.28
Margins
Gross margin is 63.81%, with operating margin of -400.12%, and net profit margin of -520.10%.
Gross Margin63.81%
Operating Margin-400.12%
Pretax Margin-520.10%
Net Profit Margin-520.10%
EBITDA Margin-386.23%
EBIT Margin-400.12%
Analyst Forecast
The average price target for CANbridge Pharmaceuticals Inc. is HK$2.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$2.00
Price Target Upside-21.26% Downside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast-40.24%
EPS Growth Forecast66.43%